Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Andecaliximab (GS-5745) in COPD
NCT02077465Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- Mar 2014
- Primary completion
- Oct 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Andecaliximab with Placebo (2 arms). Primary endpoints: Percentage of Participants Experiencing Treatment-Emergent Adverse Events, Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities and 1 more. Started Mar 2014; status: completed.
02
Drugs
andecaliximab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02077465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02077465.